



*Working to improve your health*

Market release

April 30 2018

**AFT Pharmaceuticals concludes divestment of non-core products and is to announce full year results on Wednesday May 23 2018**

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) is pleased to confirm that it has concluded agreement for AFT to divest to Baxter a range of their non-core hospital products currently sold in Australia effective 1 June 2018. This follows on from the 21 March 2018 announcement that a similar agreement had been reached for New Zealand.

Hartley Atkinson, CEO of AFT, says that we are pleased to conclude the agreement for both countries which fits in with AFT's strategy of focusing on higher margin over-the-counter products.

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) also announces that it intends to release on Wednesday May 23 2018 its financial results for the year ended March 31 2018. The release will be issued at around 09:00.

This will be followed by a presentation by management at 10:00 by teleconference. The presentation material which will be referred to by management will be issued at around 09:00 and will also be available on the company's website [aftpharm.com](http://aftpharm.com).

To attend the conference call please dial in on one of the numbers below at least five minutes before the scheduled call time, identify yourself to the operator and provide the following confirmation code: 9335 578

Confirmation code: 9335 578

Phone numbers:

Australia	02 8038 5221	New Zealand	09 8876 907
	1800 123 296		0800 452 782

[End of release]

Contact:

Malcolm Tubby

Chief Financial Officer

AFT Pharmaceuticals Ltd

Phone: +64 9 488 0232